BrdU | AAT Bioquest

BrdU

5-Bromo-2'-deoxyuridine; CAS 59-14-3

BrdU (5-bromo-2'-deoxyuridine) is a synthetic thymidine analog that incorporates into newly synthesized DNA during S-phase, enabling precise detection and quantification of cell proliferation through immunofluorescence or flow cytometry.

S-Phase Specific Incorporation: Thymidine analog integrates only during DNA synthesis (MW 307.09 Da)
Non-Radioactive Alternative: Replaces ³H-thymidine with immunodetectable bromine epitope
Antibody-Based Detection: Requires DNA denaturation (2N HCl/DNase) for epitope accessibility
Pulse-Chase Compatible: Stable incorporation enables cell lineage tracing and proliferation kinetics

Chemical structure for BrdU [5-Bromo-2'-deoxyuridine] *CAS 59-14-3*

Protocol

SDS

Catalog	Size	Price	Quantity
17030	25 mg	Price

Overview

BrdU (bromodeoxyuridine, 5-bromo-2'-deoxyuridine) is a synthetic thymidine analog widely used in cell proliferation and DNA replication studies, offering precise localization of newly synthesized DNA in both in vivo and in vitro systems via detection with anti-BrdU antibodies (available here).

Background

In modern cell biology and biomedical research, reliable identification of S-phase cells is indispensable for understanding tissue growth, regeneration, tumor progression, and other proliferation-related processes. Historically, radioactive [³H]thymidine was used to detect newly synthesized DNA but raised concerns over radioactivity handling. Non-radioactive analogs were developed to overcome these limitations, most prominently bromodeoxyuridine (BrdU), a halogenated thymidine analog that can be integrated into replicating DNA. BrdU staining and BrdU assays allow researchers to detect BrdU-incorporated DNA using immunochemical methods, enabling direct visualization of DNA replication events. Because BrdU closely mimics thymidine, it is incorporated only by actively replicating (S-phase) cells, making it a precise marker of DNA synthesis for in vivo labeling or in vitro cell culture assays.

Mechanisms and Principles of BrdU

What is BrdU?

BrdU (bromodeoxyuridine) is a synthetic thymidine analog with a bromo substituent on the 5-position of the pyrimidine ring, allowing it to replace thymidine in DNA. Once integrated, BrdU can be recognized by antibodies raised against the bromine moiety (Gratzner, 1982).

What is BrdU a marker for?

Since BrdU is incorporated only during S-phase, it serves as a direct marker of actively replicating cells. Many labs favor BrdU for pulse-chase labeling strategies to measure cell-cycle dynamics, newly generated cells in tissues, or the turnover of specific cell populations (Kee et al., 2002).

What does BrdU mimic, and what does BrdU replace?

Chemically, BrdU mimics thymidine, pairing with adenine during replication. It replaces thymidine in newly synthesized DNA strands, so newly divided cells can be detected immunochemically via anti-BrdU antibodies.

What is the principle of BrdU Assays?

Mechanistically, once BrdU is incorporated in DNA, the sample is typically denatured (2 N HCl, DNase, or other treatments) to expose BrdU epitopes. Anti-BrdU monoclonal antibodies then specifically detect these epitopes, enabling assays (immunofluorescence, flow cytometry, immunohistochemistry) to quantify the fraction of S-phase cells.

What is the difference between Ki67 and BrdU?

Ki67 is an endogenous proliferation antigen expressed in all active cell-cycle phases (G1, S, G2, M), while BrdU strictly identifies cells in S-phase (Kee et al., 2002). Therefore, Ki67 is a broader proliferation marker; BrdU is more specific for DNA replication events.

Is BrdU radioactive?

No. BrdU is non-radioactive, an advantage over older [³H]thymidine methods that require special safety protocols (Dolbeare, 1995).

Is BrdU a marker for gene expression?

No—BrdU marks DNA replication, not transcription. However, correlating S-phase labeling with subsequent expression patterns (using qPCR or microarrays) can reveal how cell-cycle entry influences gene profiles.

How long does BrdU last?

Once incorporated, BrdU remains in the DNA of that cell lineage unless dilution occurs by further divisions or by DNA repair processes. Short pulses (~30–120 min) highlight only cells that enter S-phase briefly; continuous labeling over days can accumulate a broader labeled cohort.

Integrating BrdU into Advanced Workflows

Why use BrdU?

BrdU’s S-phase specificity allows fine-grained views of cell-cycle entry and division. It’s widely adopted in regenerative biology, immuno-oncology, and neuroscience to pinpoint newly formed neurons (Kee et al., 2002) or evaluate the effects of drugs on DNA replication. Moreover, labeling viral genomes with BrdU has proven effective for sophisticated fluorescence and electron microscopy imaging techniques (Condezo & San Martín, 2021). Extended labeling should be approached with caution, as repeated or high-dose schedules can reveal or induce subtle changes in cell physiology.

How to use BrdU?

In Vivo: A single or repeated BrdU injection (~50–100 mg/kg IP in rodents) labels cells replicating DNA in a specified window.
In Vitro: Add 5–10 µM BrdU to culture media for 30 min to several hours (pulse labeling), capturing cells entering S-phase.

How do you dissolve BrdU?

BrdU can be purchased from various suppliers (including those sometimes cited as BrdU Sigma) and typically arrives as a crystalline powder. For our BrdU product, the same guidelines apply:

Exact 10 mM: Dissolve 3.07 mg of BrdU (MW ~307.09 from AAT Bioquest) in 1 mL DMSO.
Alternative: Concentrations from 1–10 mM are typical; adjust the BrdU mass accordingly (e.g., 1 mM ~0.307 mg/mL).

This DMSO stock is stable for up to 6 months at –20 °C if you avoid repeated freeze-thaw cycles.

What is the stock solution for BrdU?

In vivo injection: Many labs use 10–50 mg/mL in sterile PBS or saline.
In vitro: A 10 mM DMSO stock (~3.07 mg/mL) is common, stored at –20 °C for up to 6 months.
Working solution: For immediate experiments, prepare 5–20 µM in your buffer of choice (e.g., cell culture medium). Use promptly; discard unused portions.

Is BrdU light sensitive?

Moderately. While not as photosensitive as fluorescent dyes, it’s prudent to protect BrdU stocks from intense UV/visible light (e.g., amber vials, covering with foil).

Does BrdU stop DNA synthesis?

Generally, no—standard concentrations (1–10 µM in vitro, ~50 mg/kg in vivo) don’t halt replication but can be mutagenic at high doses.

Diermeier et at., 2004; Kee et al., 2002; Zeng et al., 2009

BrdU in IHC and Flow Cytometry: Modern Implementations

Immunohistochemistry (IHC)

BrdU-labeled tissue generally requires partial DNA denaturation (e.g., acid hydrolysis, enzymatic digestion, or heat-induced antigen retrieval) to expose BrdU epitopes. However, the selection of method and its duration can strongly influence tissue morphology and signal quality (Taupin, 2007; Molina et al., 2017). Overly long acid hydrolysis may damage delicate structures, while under-treatment can obscure the BrdU signal (Buenrostro-Jauregui et al., 2020). Different tissue types (e.g., hard tissues, spermatogenic tissue) often require fine-tuning of fixation, decalcification (if needed), and retrieval steps (Shimada et al., 2008; Wakayama et al., 2015). Recent refinements include using heat-induced antigen retrieval (HIAR) with mild buffers—an approach that preserves many co-stained epitopes more effectively than harsh acid alone, while still rendering BrdU accessible (Wakayama et al., 2015). In inflamed or necrotic regions, localized adjustments of the DNA denaturation step may be necessary to limit nonspecific binding or poor morphology (Taupin, 2007).

Key Considerations

Denaturation Method: Acid (e.g., 2 N HCl) is standard, but can compromise other epitopes or yield higher background. DNase or enzyme based protocols are gentler but need pilot tests. HIAR (e.g., 20 mM Tris HCl, pH 9.0, at ~95 °C) can preserve tissue architecture and allow multi marker co staining.
Exposure Time: Overly short denaturation yields weak signals, whereas excessive treatment causes morphological damage. Optimize for each tissue type.
Fixation and Tissue Type: Bouin’s or mild formalin in combination with special decalcifiers (for bone/teeth) can improve BrdU detection. Thicker or fibrotic sections may benefit from polymer based detection systems and carefully managed permeabilization.
Inflamed or Necrotic Zones: Tissue with infiltration or necrotic pockets may show higher background. Adjust acid or enzyme steps regionally or shorten retrieval times if morphology is compromised.
Antigen Retrieval Buffers: Mild pH 9.0 buffers under moderate heat can minimize epitope masking. For co staining with other epitopes, refine retrieval buffers that preserve additional targets.
Validation & Controls: Include negative controls (unlabeled tissue or no BrdU injection) and positive controls (known S phase hotspots). Double check with other proliferation markers (e.g., Ki67) to confirm specificity.

Flow Cytometry

Flow cytometry for BrdU labeled cells enables high throughput, multi parameter analysis of cell cycle progression, surface phenotype, and intracellular markers. Fixation/permeabilization must be carefully optimized to expose BrdU epitopes without quenching sensitive fluorophores or damaging target epitopes. Modern BrdU flow cytometry can thus simultaneously assess proliferation, apoptosis markers, and cell identity in diverse populations.

Key Considerations

Multiplexed Panel Design

Multi-Color Strategies: Modern protocols often incorporate 5+ colors simultaneously (Yu et al., 2022). It is essential to validate each fluorophore under partial acid or mild DNase steps. Confirm that tandem dyes (e.g., PE-Cy7) remain stable.

Antigen-Specific Markers: Combine DNA-synthesis detection (BrdU) with surface proteins (CD3, CD19, etc.) and intracellular antigens (e.g., cytokines or transcription factors). Detailed compensation beads and isotype controls are critical.
Fixation & Permeabilization

Gentle DNA Denaturation: Overly harsh acid can degrade tandem dyes or perturb co-staining (Nguyen et al., 2024). Some labs adopt a two-step method: mild acid (1–2 N) or partial DNase plus a gentle buffer.

Cell Type Variation: Tissue-specific cell lines (retinal cells vs. PBMCs) may tolerate different acid strengths (Vanzo-Sparks et al., 2024). Pilot runs with small sample sets are recommended.
BrdU Incorporation & Labeling

Pulse Duration: Typical exposures range from 30 min to 2 h, but the exact pulse must be verified, especially in slow-cycling lines. Extended pulses can raise background (Klapp et al., 2024).

Simultaneous Viability Analysis: Include viability dyes (7-AAD or Live/Dead) to exclude dead cells that can confound cell cycle gating.
DNA Stains & Cell Cycle Analysis

Synergistic Markers: Pair BrdU with DNA-content dyes (e.g., 7-AAD, PI, or DAPI) to refine gating for S-phase cells. Adjust compensation carefully to separate BrdU from DNA-fluor signals (Buenrostro-Jauregui et al., 2020).

M-Phase or Proliferation Markers: Combine BrdU with Ki67 or pH3 for advanced multi-parameter readouts. Confirm epitope stability after acid or DNase.
Advanced Spectral Flow or Imaging Flow

Spectral Flow Cytometry: Deconvolutes closely overlapping fluorophores, ideal for large 8+ color BrdU panels. Ensure reference controls for each fluorophore to train the unmixing algorithm.

Imaging Flow Cytometry: Merges morphological detail with BrdU positivity, enabling direct correlation of nuclear shape or subcellular marker distribution with S-phase detection (Yu et al., 2022).
Proliferation & Apoptosis

Simultaneous Apoptosis Detection: Annexin V or cleaved caspase-3 can be integrated (Nguyen et al., 2024). Verify that fixation/permeabilization conditions do not disrupt detection of these apoptotic markers.

Data Acquisition & Gating

Quality Controls: Single-stain controls, fluorescence minus one (FMO), and universal negative controls remain vital.

Batch Effects: Use consistent staining protocols, machine settings, and compensation for reliable BrdU-based quantifications (Klapp et al., 2024).
Practical Tips

Pilot Titrations: Always titer anti-BrdU antibodies in the presence of your entire panel and run small pilot tests to confirm epitope detection is unaffected by the rest of the stains.

Spillover: BrdU detection often uses FITC or Alexa Fluor 488 channels, which can spill into PE or APC. Proper unmixing or compensation is key in multi-param assays.

BrdU Side Effects, Hazards, and Induced Senescence

What are the hazards of BrdU?

BrdU is a mild mutagen requiring standard precautions (gloves, coat, disposal). In many mutagenesis assays, BrdU is paired with Category 1 carcinogens (the most potent and toxic carcinogens), such as aflatoxin B1 and benzo[a]pyrene, which pose significantly higher risk and demand stricter handling.

Is BrdU radioactive?

No. That remains a central advantage over [³H]thymidine-based approaches.

Does BrdU cause significant toxicity?

Typically not at recommended doses. However, excessive concentrations can trigger partial replication stalling (Sakamoto et al., 2004). Monitoring cell viability and proliferation rates after BrdU administration is recommended to avoid confounding results.

Side Effects of BrdU

At typical research doses, side effects remain mild, though repeated or prolonged high-dose exposures increase the risk of base misincorporations and potential mutagenicity (Lehner et at., 2011). Some studies suggest that extended exposures to BrdU can increase cytotoxicity or alter replication kinetics in certain lines (Haskins et al., 2020). The potential for “birth-dating” inaccuracies can arise when labeling windows are not precisely controlled, as timing overlaps might confound cell lineage tracing (Rowell & Ragsdale, 2012). Other studies emphasize the importance of acid or exonuclease treatments to minimize spurious artifacts in labeling (Ligasová et al., 2017). In cancer research, continuous BrdU exposure has even been shown to alter cell cycle progression differentially in certain tumor lines (Diermeier et al., 2004). Recent work has also revealed that BrdU can disrupt direct astrocyte-to-neuron reprogramming by curtailing reprogramming efficiency and exacerbating cell death, underscoring the need for caution in using BrdU for lineage-tracing studies involving neuronal fate conversion (Wang et al., 2021).

BrdU-Induced Senescence and Implications

BrdU can trigger senescent-like changes in stem and progenitor cells, particularly under high-frequency or long-term BrdU labeling. Even a single, low-dose BrdU pulse in cultured neural progenitors can lead to notable antiproliferative effects, altered differentiation, and increased expression of hallmark senescence markers such as senescence-associated β-galactosidase (SA-β-Gal) and γ-H2AX, suggesting progressive functional deficits in cells that persist in dividing (Ross et al., 2008). These effects are being explored as potential therapeutic avenues for cancer (Wang, 2022; Restelli, 2024). Recently, a mechanism of BrdU-induced senescence has been elucidated: BrdU’s substitution for thymidine can destabilize nucleosomes by interfering with the histone H2B basic domain (HBR), a domain that normally helps anchor DNA around nucleosomes. When this HBR function is disturbed, nucleosome organization is disrupted, resulting in misregulated gene expression and eventual senescent phenotypes (En et al., 2022).

Because senescence involves multiple pathways, fully understanding BrdU-induced senescence often requires assessing more than just BrdU labeling (González-Gualda et al,. 2021). For instance, upregulated SA-β-Gal can be quantified at single-cell resolution with neutral, user-friendly kits such as Cell Meter™ Cellular Senescence Activity Assay Kits (green or red), which readily permeates live cells and quantifies SA-β-Gal under standard fluorescence microscopy or flow cytometry. In parallel, measuring reactive oxygen species (ROS)—key drivers of both DNA damage and senescence—is possible with Cell Meter™ Fluorimetric Intracellular Total ROS Detection Kits (various colors and formats). Both protocols are compatible with typical imaging or cytometric systems and can be used alongside, or instead of, BrdU-based assays for experiments focusing on senescence. This combined approach—tracking BrdU-labeled cells for replicative events while simultaneously probing SA-β-Gal or oxidative stress—provides a more comprehensive read on the onset and progression of BrdU-induced senescence. More information on cell senescence analysis can be found here.

Comparisons with Other Quantification Methods

BrdU vs. EdU

EdU (5-ethynyl-2′-deoxyuridine) detects newly synthesized DNA through copper-catalyzed azide-alkyne cycloaddition (CuAAC), eliminating the need for acid or DNase. This milder click-chemistry approach preserves protein conformations and cell architecture, making EdU ideal for multiplex immunostaining or extended phenotyping. However, variations in nucleoside transport or salvage pathways can lower EdU incorporation in certain cell types (Masson et al., 2021). Copper-based toxicity can also arise in sensitive cell lines unless optimized, and EdU has been shown to have adverse long-term effects on hippocampal neurogenesis (Ivanova et al., 2022). BrdU remains the “classic” choice for those requiring established antibody panels or robust immunodetection protocols.

BrdU vs. Tritiated Thymidine (3H-thymidine, 3H-TdR)

Historically, ³H-TdR provided a direct measure of DNA synthesis via autoradiography, but its radioactivity handling and incompatibility with advanced multiplex assays complicate modern use (Ivanova et al., 2022; Masson et al., 2021). Nevertheless, evidence suggests that ³H-TdR labeling causes fewer disruptions to proliferating neuroblasts or their progeny compared to BrdU, as the only difference from native thymine is an extra neutron (Martí-Clúa, 2021). In contrast, BrdU—though non-radioactive and more convenient for fluorescent detection—can introduce base mispairing with guanine instead of adenine, sometimes leading to DNA breaks, mutations, and negative impacts on neuroblast differentiation and neuron fate (Martí-Clúa, 2021). ³H-TdR remains valuable to closely reflect normal DNA for more accurate neurogenetic timetables, but is typically overshadowed by BrdU for simpler labeling protocols and compatibility with diverse fluorescent assays.

Advanced Alternatives: Bucculite™ XdU and FdU

Bucculite™ XdU and FdU assays replace BrdU’s antibody-based detection with alkyne-containing thymidine analogs (XdU) that bind fluorescence tags without denaturation steps, preserving morphology, sample integrity, and epitope binding sites. These assays facilitate multiplex staining with fluorescent proteins or cell surface markers, and the entire process—including washes—typically completes in under an hour while remaining compatible with both standard microscopy and flow cytometry, optimizing workflow. Copper-free FdU variants further reduce potential toxicity or autofluorescence, offering multiple fluorescence channels and broader applicability to sensitive cell lines.

Further Reading

View All

Bialic, Marta, et al. "Measuring S-Phase Duration from Asynchronous Cells Using Dual EdU-BrdU Pulse-Chase Labeling Flow Cytometry." Genes (Basel), vol. 13, no. 3, 2022, p. 408.
Buenrostro-Jauregui, M., Tapia-de-Jesús, A., Mata, J., et al. “Immunohistochemistry Techniques to Analyze Cellular Proliferation and Neurogenesis in Rats Using the Thymidine Analog BrdU.” Journal of Visualized Experiments, no. 163, 2020, doi:10.3791/61483.
Buenrostro-Jauregui, M., Tapia-de-Jesús, A., Mata, J., et al. “Immunohistochemistry Techniques to Analyze Cellular Proliferation and Neurogenesis in Rats Using the Thymidine Analog BrdU.” Journal of Visualized Experiments, no. 163, 2020, doi:10.3791/61483.
Burclaff, Joseph, et al. "Proliferation and Differentiation of Gastric Mucous Neck and Chief Cells During Homeostasis and Injury-Induced Metaplasia." Gastroenterology, vol. 158, no. 3, 2021, pp. 598–609.e5.
Chang, P. C., Lin, Y. C., Yen, H. J., et al. “Ancient Ubiquitous Protein 1 (AUP1) Is a Prognostic Biomarker Connected with TP53 Mutation and the Inflamed Microenvironments in Glioma.” Cancer Cell International, vol. 23, no. 1, 2023, p. 62, doi:10.1186/s12935-023-02912-y.
Condezo, G. N., and C. San Martín. "Bromodeoxyuridine Labelling to Determine Viral DNA Localization in Fluorescence and Electron Microscopy: The Case of Adenovirus." Viruses, vol. 13, no. 9, 2021, p. 1863.
Diermeier, S., et al. "Exposure to Continuous Bromodeoxyuridine (BrdU) Differentially Affects Cell Cycle Progression of Human Breast and Bladder Cancer Cell Lines." Cell Proliferation, vol. 37, no. 2, 2004, pp. 195–206.
Dolbeare, F. "Bromodeoxyuridine: A Diagnostic Tool in Biology and Medicine, Part I: Historical Perspectives, Histochemical Methods and Cell Kinetics." Histochemical Journal, vol. 27, no. 5, 1995, pp. 339–369.
Dovmark, Tobias H., et al. "Quantitative Assessment of Epithelial Proliferation in Rat Mammary Gland Using Artificial Intelligence Independent of Choice of Proliferation Marker." Journal of Histochemistry and Cytochemistry, vol. 70, no. 3, 2022, pp. 237–250.
En A, Watanabe K, Ayusawa D, Fujii M. “The key role of a basic domain of histone H2B N-terminal tail in the action of 5-bromodeoxyuridine to induce cellular senescence.” FEBS J. 2022. doi:10.1111/febs.16584
González-Gualda, E., Baker, A.G., Fruk, L. and Muñoz-Espín, D. (2021), A guide to assessing cellular senescence in vitro and in vivo. FEBS J, 288: 56-80. https://doi.org/10.1111/febs.15570
Gratzner, H. G. "Monoclonal Antibody to Bromodeoxyuridine: A New Reagent for Detection of DNA Replication." Science, vol. 218, no. 4571, 1982, pp. 474–475.
Haskins, J. S., et al. "Evaluating the Genotoxic and Cytotoxic Effects of Thymidine Analogs, 5-Ethynyl-2′-Deoxyuridine and 5-Bromo-2′-Deoxyurdine to Mammalian Cells." International Journal of Molecular Sciences, vol. 21, no. 18, 2020, p. 6631.
Huang, L., Xu, Z., Lei, X., et al. “Paneth Cell-Derived iNOS Is Required to Maintain Homeostasis in the Intestinal Stem Cell Niche.” Journal of Translational Medicine, vol. 21, no. 1, 2023, p. 852, doi:10.1186/s12967-023-04744-w.
IARC. Some Chemicals that Cause Tumours of the Kidney or Urinary Bladder in Rodents and Some Other Substances (IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Vol. 73). International Agency for Research on Cancer, 1999.
Ivanova, Anna, et al. "Synthetic Thymidine Analog Labeling without Misconceptions." Cells, vol. 11, no. 12, 2022, p. 1888.
Kee, N., et al. "The Utility of Ki67 and BrdU as Markers of Adult Neurogenesis." Journal of Neuroscience Methods, vol. 115, no. 2, 2002, pp. 97–105.
Klapp, V., Bloy, N., Jiménez-Cortegana, C., et al. “Flow Cytometry-Assisted Quantification of Cell Cycle Arrest in Cancer Cells Treated with CDK4/6 Inhibitors.” In Methods in Cell Biology, vol. 181, 2024, pp. 197–212, doi:10.1016/bs.mcb.2023.02.018.
Lao, Y., Bai, Y., Guan, X., et al. “Sertraline Alleviates Chronic Prostatitis by Regulating the TRPV1 Channel.” Journal of Inflammation Research, vol. 17, 2024, pp. 4257–4275, doi:10.2147/JIR.S458132.
Lehner B., Sandner B., Marschallinger J., Lehner C., Furtner T., Couillard-Despres S., Rivera F.J., Brockhoff G., Bauer H.C., Weidner N., et al. The dark side of BrdU in neural stem cell biology: Detrimental effects on cell cycle, differentiation and survival. Cell Tissue Res. 2011;345:313–328. doi: 10.1007/s00441-011-1213-7.
Ligasová, A., et al. "Looking for Ugly Ducklings: The Role of the Stability of BrdU-Antibody Complex and the Improved Method of the Detection of DNA Replication." PLoS One, vol. 12, no. 3, 2017, e0174893.
Maecker, H. T., et al. "Selecting Fluorochrome Conjugates for Maximum Sensitivity." Cytometry A, vol. 62, no. 2, 2004, pp. 169–173.
Martí-Clúa J. Incorporation of 5-Bromo-2'-deoxyuridine into DNA and Proliferative Behavior of Cerebellar Neuroblasts: All That Glitters Is Not Gold. Cells. 2021 Jun 10;10(6):1453. doi: 10.3390/cells10061453. PMID: 34200598; PMCID: PMC8229392.
Masson, Thibaut, et al. “BrdU Immuno-Tagged G-Quadruplex Ligands: A New Ligand-Guided Immunofluorescence Approach for Tracking G-Quadruplexes in Cells.” Nucleic Acids Research, vol. 49, no. 22, 2021, pp. 12644–12660.
Miller, M. W., and R. S. Nowakowski. "Use of Bromodeoxyuridine-Immunohistochemistry to Examine the Proliferation, Migration, and Time of Origin of Cells in the Central Nervous System." Brain Research, vol. 457, no. 1, 1988, pp. 44–52.
Molina, V., Rodríguez-Vázquez, L., Owen, D., et al. “Cell Cycle Analysis in the Rat External Granular Layer Evaluated by Several Bromodeoxyuridine Immunoperoxidase Staining Protocols.” Histochemistry and Cell Biology, vol. 148, no. 5, 2017, pp. 477–488, doi:10.1007/s00418-017-1593-1.
Nguyen, D. C., Saney, C., Hentenaar, I. T., et al. “Majority of Human Circulating IgG Plasmablasts Stop Blasting in a Cell-Free Pro-Survival Culture.” Scientific Reports, vol. 14, no. 1, 2024, p. 3616, doi:10.1038/s41598-024-53977-2.
Restelli C, Ruella M, Paruzzo L, Tarella C, Pelicci PG, Colombo E. Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia. Blood Cancer Discov. 2024 Jul 1;5(4):234-248. doi: 10.1158/2643-3230.BCD-23-0202. PMID: 38904305; PMCID: PMC11215380.
Ross, H. H., et al. "Bromodeoxyuridine Induces Senescence in Neural Stem and Progenitor Cells." Stem Cells, vol. 26, no. 12, 2008, pp. 3218–3227.
Rothaeusler, K., and N. Baumgarth. "Evaluation of Intranuclear BrdU Detection Procedures for Use in Multicolor Flow Cytometry." Cytometry A, vol. 69, no. 4, 2006, pp. 249–259.
Rowell, J. J., and C. W. Ragsdale. "BrdU Birth Dating Can Produce Errors in Cell Fate Specification in Chick Brain Development." Journal of Histochemistry and Cytochemistry, vol. 60, no. 11, 2012, pp. 801–810.
Sharma, Rohit B., et al. "DNA Damage Does Not Cause BrdU Labeling of Mouse or Human β-Cells." Diabetes, vol. 68, no. 5, 2019, pp. 975–987.
Shimada, A., Shibata, T., Komatsu, K., et al. “Improved Methods for Immunohistochemical Detection of BrdU in Hard Tissue.” Journal of Immunological Methods, vol. 339, no. 1, 2008, pp. 11–16, doi:10.1016/j.jim.2008.07.013.
Song, J., Sun, D. L., Li, C. Y., et al. “TL1A Promotes Fibrogenesis in Colonic Fibroblasts via the TGF-β1/Smad3 Signaling Pathway.” Current Medical Science, vol. 44, no. 3, 2024, pp. 519–528, doi:10.1007/s11596-024-2875-1.
Taupin, P. “BrdU Immunohistochemistry for Studying Adult Neurogenesis: Paradigms, Pitfalls, Limitations, and Validation.” Brain Research Reviews, vol. 53, no. 1, 2007, pp. 198–214, doi:10.1016/j.brainresrev.2006.08.002.
Vanzo-Sparks, H. K., Webster, S. E., Webster, J. M., et al. “Quantification of Proliferating and Mitotically Active Retinal Cells in Mice by Flow Cytometry.” Bio Protocol, vol. 14, no. 13, 2024, p. e5024, doi:10.21769/BioProtoc.5024.
Wakayama, T., Nakata, H., Kumchantuek, T., et al. “Identification of 5-Bromo-2′-Deoxyuridine-Labeled Cells during Mouse Spermatogenesis by Heat-Induced Antigen Retrieval in Lectin Staining and Immunohistochemistry.” Journal of Histochemistry & Cytochemistry, vol. 63, no. 3, 2015, pp. 190–205, doi:10.1369/0022155414564870.
Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022 Jun;22(6):340-355. doi: 10.1038/s41568-022-00450-9. Epub 2022 Mar 3. PMID: 35241831.
Wu, H. T., Lin, J., Liu, Y. E., et al. “Luteolin Suppresses Androgen Receptor-Positive Triple-Negative Breast Cancer Cell Proliferation and Metastasis by Epigenetic Regulation of MMP9 Expression via the AKT/mTOR Signaling Pathway.” Phytomedicine, vol. 81, 2021, p. 153437, doi:10.1016/j.phymed.2020.153437.
Yu, J., Wang, Z., Wang, Y. “BrdU Incorporation Assay to Analyze the Entry into S Phase.” In Methods in Molecular Biology, vol. 2579, 2022, pp. 209–226, doi:10.1007/978-1-0716-2736-5_16.
Zeng C, Pan F, Jones LA, Lim MM, Griffin EA, Sheline YI, Mintun MA, Holtzman DM, Mach RH. Evaluation of 5-ethynyl-2'-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. Brain Res. 2010 Mar 10;1319:21-32. doi: 10.1016/j.brainres.2009.12.092. Epub 2010 Jan 11. PMID: 20064490; PMCID: PMC2826567.

Calculators

Common stock solution preparation

Table 1. Volume of DMSO needed to reconstitute specific mass of BrdU [5-Bromo-2'-deoxyuridine] *CAS 59-14-3* to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.

	0.1 mg	0.5 mg	1 mg	5 mg	10 mg
1 mM	325.637 µL	1.628 mL	3.256 mL	16.282 mL	32.564 mL
5 mM	65.127 µL	325.637 µL	651.275 µL	3.256 mL	6.513 mL
10 mM	32.564 µL	162.819 µL	325.637 µL	1.628 mL	3.256 mL

Molarity calculator

Enter any two values (mass, volume, concentration) to calculate the third.

Mass (Calculate)		Molecular weight		Volume (Calculate)		Concentration (Calculate)		Moles
mg	÷	307.09 g/mol	=	mL	x	mM	=	mmol

Citations

View all 3 citations: Citation Explorer

PCBP1-AS1 facilitates liver metastasis in pancreatic cancer by modulating miR-125b-5p in Tumor-derived exosomes to target TNFAIP3

Authors:

Wang, Qi and Zhang, Jie and Wang, Hao and Na, Li and Wang, Xinqing and Zhang, Yang and De, Tianyu and Luo, Yongyun

Journal:

BMC Cancer (2025): 1--21

SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia

Authors:

Lee, Ching-Tien and Lin, Kun-Der and Hsieh, Cheng-Fang and Wang, Jiz-Yuh

Journal:

Biomedicines (2023): 36

Heat-shock pre-treatment reduces liver injury and aids liver recovery after partial hepatectomy in mice

Authors:

Oka, Yousuke and Akagi, Yoshito and Kinugasa, Tetsushi and Ishibashi, Nobuya and Iwakuma, Nobutaka and Shiratsuchi, Ichitarou and Shirouzu, Kazuo

Journal:

Anticancer research (2013): 2887--2894

References

View all 55 references: Citation Explorer

DNA interstrand crosslinks are induced in cells prelabelled with 5-bromo-2'-deoxyuridine and exposed to UVC radiation

Authors:

Wojcik A, Bochenek A, Lankoff A, Lisowska H, Padjas A, Szumiel I, von Sonntag C, Obe G.

Journal:

J Photochem Photobiol B (2006): 15

Estrogen-induced region specific decrease in the density of 5-bromo-2-deoxyuridine-labeled cells in the olfactory bulb of adult female rats

Authors:

Hoyk Z, Varga C, Parducz A.

Journal:

Neuroscience (2006): 1919

Sequence-dependent formation of intrastrand crosslink products from the UVB irradiation of duplex DNA containing a 5-bromo-2'-deoxyuridine or 5-bromo-2'-deoxycytidine

Authors:

Zeng Y, Wang Y.

Journal:

Nucleic Acids Res. (2006)

Exposure to 5-bromo-2'-deoxyuridine induces oxidative stress and activator protein-1 DNA binding activity in the embryo

Authors:

Sahambi SK, Hales BF.

Journal:

Birth Defects Res A Clin Mol Teratol (2006): 580

The evaluation of early embryonic neurogenesis after exposure to the genotoxic agent 5-bromo-2'-deoxyuridine in mice

Authors:

Kuwagata M, Ogawa T, Nagata T, Shioda S.

Journal:

Neurotoxicology. (2006)

Physical properties

Molecular weight	307.09
Solvent	DMSO

Storage, safety and handling

H-phrase	H303, H313, H333
Hazard symbol	XN
Intended use	Research Use Only (RUO)
R-phrase	R20, R21, R22
Storage	Freeze (< -15 °C); Minimize light exposure
UNSPSC	41116134
CAS	59-14-3

Documents

Protocol
Safety Data Sheet
Certificate of Analysis
Brochure: Cell Apoptosis & Proliferation
Brochure: Cell Viability & Proliferation

Telephone
Fax
Email	sales@aatbio.com
International	See distributors
Bulk request	Inquire
Custom size	Inquire
Technical Support	Contact us
Request quotation	Request
Purchase order	Send to sales@aatbio.com
Shipping	Standard overnight for United States, inquire for international

Page updated on January 18, 2025